Objectives

Identify the federal regulations covering clinical research and clinical investigator obligations

Discuss specific problems seen during FDA inspections at clinical sites

Discuss various methods that can be used to ensure compliance with federal regulations and study protocol requirements
Who is an Investigator?

- An individual **who actually conducts a clinical investigation** (i.e., under whose immediate direction the drug is dispensed to a subject.)

- In the event an investigation is conducted by a team of individuals, the investigator is **the responsible leader** of the team.

[21 CFR 312.3]
QUESTION?

Can there be co-investigators?

**ANSWER:** Yes and No. Yes, for your needs but NO for regulatory purposes. Each co-investigator is fully responsible for fulfilling all of the obligations of an investigator; each must sign a separate Form FDA-1572.
Sponsor-Investigator

An individual who **both initiates and conducts an investigation**, and under whose immediate direction the investigational drug is administered or dispensed.

- The term does not include any person other than an individual.
- The requirements applicable to a sponsor-investigator include both those applicable to an investigator and a sponsor.

[21 CFR 312.3]
Question:

Does the investigator have to be a medical doctor?

**Answer:** NO A physician can be a subinvestigator to perform those study functions requiring the appropriate level of medical expertise.

[21 CFR 312.53]
Legal Framework

- Federal Food, Drug, and Cosmetic Act (FD&C Act)
  - Section 505(i) is the statutory authority for FDA’s oversight of clinical investigations to test safety and effectiveness

- Code of Federal Regulations (CFR)
  - Regulations promulgated under Section 505(i) describing FDA’s authority over the conduct of clinical investigations including
    - Sponsor responsibilities
    - Clinical Investigator responsibilities

- Guidances
  - Advisory only, to assist clinical investigators and sponsors in complying with the regulations
Know the laws of your state

Example: What is the legal age for consent to enroll in a clinical trial?

Answer: Depends on the applicable law of the jurisdiction in which the investigation will be conducted. [21 CFR 50.3(o)]

• Certain life events like military service, marriage, pregnancy and childbirth may allow consent
Reference

- **Institute of Medicine Report**
  Ethical Conduct of Clinical Research Involving Children

See Appendix B:
STATE REGULATION OF MEDICAL RESEARCH WITH CHILDREN AND ADOLESCENTS: AN OVERVIEW AND ANALYSIS

FDA Expectations of Clinical Investigators

- Adherence to Code of Federal Regulations
  - Knowledge of Clinical Investigator regulations
  - Understanding of Clinical Investigator responsibilities
Expectations

If you don’t like doing paperwork…

Run as fast as you can towards the door.
No investigator may participate in an investigation until he/she provides the sponsor with a completed, signed Statement of Investigator, Form FDA 1572

[21 CFR 312.53(c)].
**DEPARTMENT OF HEALTH AND HUMAN SERVICES**  
**FOOD AND DRUG ADMINISTRATION**

**STATEMENT OF INVESTIGATOR**  
*(TITLE 21, CODE OF FEDERAL REGULATIONS (CFR) PART 312)*

(See instructions on reverse side.)

**NOTE:** No investigator may participate in an investigation until he/she provides the sponsor with a completed, signed Statement of Investigator, Form FDA 1572 (21 CFR 312.53(c)).

### 1. NAME AND ADDRESS OF INVESTIGATOR

Name of Principal Investigator

<table>
<thead>
<tr>
<th>Address 1</th>
<th>Address 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>City</td>
<td>State/Province/Region</td>
</tr>
</tbody>
</table>

### 2. EDUCATION, TRAINING, AND EXPERIENCE THAT QUALIFY THE INVESTIGATOR AS AN EXPERT IN THE CLINICAL INVESTIGATION OF THE DRUG FOR THE USE UNDER INVESTIGATION. ONE OF THE FOLLOWING IS PROVIDED *(Select one of the following.)*

- [ ] Curriculum Vitae
- [ ] Other Statement of Qualifications

### 3. NAME AND ADDRESS OF ANY MEDICAL SCHOOL, HOSPITAL, OR OTHER RESEARCH FACILITY WHERE THE CLINICAL INVESTIGATION(S) WILL BE CONDUCTED

Name of Medical School, Hospital, or Other Research Facility

<table>
<thead>
<tr>
<th>Address 1</th>
<th>Address 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>City</td>
<td>State/Province/Region</td>
</tr>
</tbody>
</table>

**CONTINUATION PAGE for Item 3**

### 4. NAME AND ADDRESS OF ANY CLINICAL LABORATORY FACILITIES TO BE USED IN THE STUDY

Name of Clinical Laboratory Facility

<table>
<thead>
<tr>
<th>Address 1</th>
<th>Address 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>City</td>
<td>State/Province/Region</td>
</tr>
</tbody>
</table>

**CONTINUATION PAGE for Item 4**

### 5. NAME AND ADDRESS OF THE INSTITUTIONAL REVIEW BOARD (IRB) THAT IS RESPONSIBLE FOR REVIEW AND APPROVAL OF THE STUDY(IES)

Name of IRB

**CONTINUATION PAGE for Item 5**
9. COMMITMENTS

I agree to conduct the study(ies) in accordance with the relevant, current protocol(s) and will only make changes in a protocol after notifying the sponsor, except when necessary to protect the safety, rights, or welfare of subjects.

I agree to personally conduct or supervise the described investigation(s).

I agree to inform any patients, or any persons used as controls, that the drugs are being used for investigational purposes and I will ensure that the requirements relating to obtaining informed consent in 21 CFR Part 50 and institutional review board (IRB) review and approval in 21 CFR Part 56 are met.

I agree to report to the sponsor adverse experiences that occur in the course of the investigation(s) in accordance with 21 CFR 312.64. I have read and understand the information in the investigator’s brochure, including the potential risks and side effects of the drug.

I agree to ensure that all associates, colleagues, and employees assisting in the conduct of the study(ies) are informed about their obligations in meeting the above commitments.

I agree to maintain adequate and accurate records in accordance with 21 CFR 312.62 and to make those records available for inspection in accordance with 21 CFR 312.66.

I will ensure that an IRB that complies with the requirements of 21 CFR Part 56 will be responsible for the initial and continuing review and approval of the clinical investigation. I also agree to promptly report to the IRB all changes in the research activity and all unanticipated problems involving risks to human subjects or others. Additionally, I will not make any changes in the research without IRB approval, except where necessary to eliminate apparent immediate hazards to human subjects.

I agree to comply with all other requirements regarding the obligations of clinical investigators and all other pertinent requirements in 21 CFR Part 312.

10. DATE (mm/dd/yyyy)  11. SIGNATURE OF INVESTIGATOR

(WARNING: A willfully false statement is a criminal offense. U.S.C. Title 18, Sec. 1001.)
Commitments on 1572

- Personally conduct or supervise investigation
- Follow protocol- only make changes after notifying the sponsor unless subject at risk
- Ensure all persons assisting with the study are informed of obligations
- Inform subjects that drugs are being used for investigational purposes
- Ensure informed consent (21 CFR Part 50) and IRB review, approval and reporting (21 CFR Part 56)
- Report to sponsor adverse events (21 CFR 312.64); read and understand the IB.
Commitments (cont.)

- Maintain adequate and accurate records (21 CFR 312.62) and make them available for inspection in accordance with 21 CFR 312.68
- Ensure initial and continuing review by an IRB and report all changes to research and unanticipated problems involving risks to subjects, not make any changes without IRB approval except where necessary to eliminate immediate hazards
- Comply with other requirements in 21 CFR 312
Form FDA 1572

- If a clinical study is conducted outside of the U.S. and is not conducted under an investigational new drug application (IND), then the investigator need not sign a 1572.

- If a foreign clinical study is conducted under an IND, then all FDA IND regulations, including the requirement to obtain a signed 1572, must be met.

- If local laws or regulations prohibit the signing of a 1572, FDA would expect the sites to operate as non-IND sites.
Information Sheet
Guidance for Sponsors, Clinical Investigators, and IRBs

Frequently Asked Questions – Statement of Investigator (Form FDA 1572)

U.S. Department of Health and Human Services
Food and Drug Administration
Office of Good Clinical Practice
Center for Drug Evaluation and Research (CDER)
Center for Biologics Evaluation and Research (CBER)

May 2010
Procedural
E6: Good Clinical Practice: Consolidated Guideline

Published as official guidance in U.S. Federal Register (May 1997)

- “The objective of this ICH GCP guidance is to provide a **unified standard** for the European Union (EU), Japan, and the United States to facilitate the mutual acceptance of clinical data by the regulatory authorities in these jurisdictions.”
In General...E6 More Detailed

- Differences can especially be seen in the area of Sponsor responsibilities
  - ICH E6 more detailed for monitoring and QA
- However, FDA regulations are more explicit in the IRB sections
Question?

Do FDA regulations allow for delegation of the informed consent?
Answer: Not really but...

- FDA has no regulations concerning delegation of this duty
  - Discussed in the FDA Information Sheets: “FDA does not require the investigator to personally conduct the consent interview.”
  - [http://www.fda.gov/RegulatoryInformation/Guidances/ucm126431.htm](http://www.fda.gov/RegulatoryInformation/Guidances/ucm126431.htm)

- ICH allows the delegation of the informed consent process to a designee
  - “The investigator, or a person designated by the investigator, should fully inform the subject…”
Question?

*Does the investigator have to sign the informed consent?*

**ANSWER:** NO Signing/dating by person conducting the informed consent discussion is part of ICH-GCP but not FDA regulations.
Role of Clinical Investigators

- Good Clinical Practice (GCP) in FDA-regulated research is not the same as good clinical practice in caring for patients
  - For example, FDA regulations have very specific requirements for following the protocol, recordkeeping, and drug accountability
Important Caveat for Clinical Investigators

Standards for clinical care of patients ≠ Standards for academic research ≠ Standards for FDA regulated research

“Therapeutic experimentation did not begin to gain a true foothold in modern medicine until the U.S. legal system stopped equating experimentation with medical malpractice”.

- Overview on FDA History
Historical Perspective

1961-1962: Thalidomide tragedy

Exposed loopholes in Food, Drug and Cosmetic Act of 1938: Companies could distribute unapproved drugs for experimental purposes

- Did not require notification to patients of investigational status
- Did not require companies or doctors to keep track of distribution
- Did not require FDA to be notified of experimental use
- Did not require records to be kept
- Did not require demonstration of drug effectiveness
1962: Kefauver-Harris Amendments

- Approval based on demonstration of **efficacy** as well as safety (*1938 Food, Drug, and Cosmetic Act only required safety evaluation*)
- Expanded inspectional authority - FDA can inspect company records regarding development and clinical testing
- FDA must be notified before clinical trials could be conducted
- Rulemaking authority over “Investigational New Drugs”
- Gave FDA the power to halt clinical trials
**Additional Actions**

**IND Regulations of 1963**
- Created the current framework of clinical trials
- Investigations must be “adequate” and “well-controlled”
- Investigators qualified by scientific training and experience
- Recordkeeping requirements
- Informed consent of subjects
Who’s in Charge at the Study Site?

- The clinical investigator is in charge and held accountable
  - FDA regulations permit sponsors to delegate their responsibilities to contract research organizations (CROs) but do not permit clinical investigators to delegate their general responsibilities to CROs or site management organizations, subinvestigators, or study staff

- Penalties for significant noncompliance
  - Warning Letters (posted on FDA website)
  - Disqualifications/Restrictions/Debarments (posted on FDA website)
  - Criminal prosecutions/prison/fines
Question

What documents must be submitted to the IRB for review?
Answer

- FDA: The IRB should receive and review all research activities
  - Copies of all research proposals reviewed, scientific evaluations, if any, that accompany the proposals, approved sample consent documents, progress reports submitted by investigators, and reports of injuries to subjects [21 CFR 56.115]

- FDA Guidance: The documents reviewed should include the complete documents received from the clinical investigator, such as the protocol, the investigator's brochure, a sample consent document and any advertising intended to be seen or heard by prospective study subjects.

- ICH specifically requires IRB submission of:
  - informed consent, protocol/amendments, and advertisements
  - Written information provided to subjects
  - Information about subject payment/compensation
  - Investigator’s Brochure
  - Investigator's current CV and/or qualifications
General Clinical Investigator Responsibilities [21 CFR 312.60]

- Ensuring that an investigation is conducted according to the
  - Signed investigator statement (Form 1572)
  - Investigational plan
  - Applicable regulations
- Protecting the rights, safety, and welfare of subjects under the investigator's care
- Control of drugs under investigation
- Ensuring that informed consent is adequately obtained according to 21 CFR 50
- Ensuring IRB review, approval and reporting requirements are met per 21 CFR 56
Investigator Responsibilities

- Control of investigational drug (312.61)
- Record keeping and retention (312.62)
  - An investigator is responsible for:
    - Maintaining adequate records of the disposition of the drug
    - Accurate case histories that record all observations, and
    - Other data pertinent to the investigation on each individual administered the investigational drug or employed as a control in the investigation
  - An investigator is required to maintain investigation records for:
    - 2 years following the date a marketing application is approved for the drug for the indication for which it is being investigated
    - 2 years after the investigation is discontinued and FDA is notified if no application is to be filed or if the application has not been approved for such indication
Responsibilities (cont.)

- Investigator reports (312.64)
  - Progress reports to sponsor
  - Safety reports
    - Immediately report any adverse event that is alarming (e.g. an unexpected event that is serious or life-threatening)
    - Record nonserious adverse events and report them to the sponsor according to the timetable for reporting specified in the protocol
- Final report to sponsor
- Financial disclosure to sponsor (21 CFR 54)
  - Promptly update as needed during the course of the investigation and for 1 year following study completion
FORMS FDA 3454 (Certification of no disclosable financial interests) and 3455 (Disclosure Statement [21 CFR § 54.4(a)]) are available on the Web at the following Internet address:

http://www.fda.gov/AboutFDA/ReportsManualsForms/Forms/default.htm
Question?

- You must disclose significant equity interest in the sponsor of a covered study.
  - What is the monetary amount of **stock** in a nonpublicly traded corporation?
    - Any amount
  - What is considered for a publicly traded corporation?
    - $50,000
  - To whom does this apply?
    - Investigator, subinvestigator, spouses and dependent children
Sponsor Responsibilities

Sponsors are responsible for (21 CFR 312.50):

- Selecting qualified investigators
- Providing them with the information they need to conduct the investigation properly
- Ensuring proper monitoring of the investigation
- Ensuring that the investigation is conducted in accordance with the general investigational plan
- Maintaining an effective IND
- Ensuring that the FDA and all participating investigators are promptly informed of significant new adverse effects or risks
Outlines FDA expectations for study oversight

- **Delegation** of study tasks
- **Training** of study staff
- **Supervision** of conduct of ongoing study
- **Oversight of third parties** involved in the study (e.g. SMOs, outside labs specifically retained to conduct study assessments)

Guidance (cont.)

Outlines FDA expectations for protecting the rights, safety, and welfare of subjects
- Provision of reasonable medical care for issues related to study participation (e.g. to manage an adverse event)
- Facilitation of care for other health issues that might arise during the study
- Avoiding exposure of subjects to unreasonable risks
Question?

Can the investigator delegate the activities around investigational product?
FDA has no regulation concerning delegation of these duties

- The investigator should ensure that any individual to whom a task is delegated is qualified by education, training, and experience (and state licensure where relevant) to perform the delegated task *(per FDA Investigator Guidance 2009)*.

ICH allows the delegation of study drug dispensing, patient counselling, and drug accountability to an “appropriate” designee.
In Summary

- Follow the **current** protocol
- **Personally** conduct or supervise investigation(s)
  - Ensure that all persons assisting in conduct of studies are informed of their obligations
- Ensure informed consent (21 CFR 50) and IRB review, approval, and reporting (21 CFR 56) requirements are met
In Summary (cont.)

- Obtain the informed consent of each human subject to whom the drug is administered
- Notify the sponsor before making changes in the protocol
- Notify the IRB and obtain IRB approval before making changes in the protocol
- Report adverse events to the sponsor
In Summary (cont.)

- Maintain adequate and accurate records
- Make records available for inspection
- Comply with all other requirements in 21 CFR 312
- Report Financial Interests to the Sponsor
DON’T

- Over-delegate to non-physicians (e.g., diagnosis that qualifies/determines eligibility for entry into the study)
- Erase, white-out or obliterate original data entry
- Accept suggested changes to study data without checking the source documents or without justification for such changes
- Backdate the consent forms and signatures
- Forget to obtain IRB approval of consent form revisions
- Revise the protocol without obtaining the sponsor’s written concurrence
- Use your staff as subjects in a study not having the condition(s) under investigation
- Destroy study records
Regulatory Authority to Conduct Inspections/Audits

- Section 505(k)(2) of the Food, Drug, and Cosmetic Act mandates that FDA shall have access to and copy and verify the required clinical study records.
- 21 CFR 312.68
  - “An investigator shall upon request from any properly authorized officer or employee of FDA, at reasonable times, permit such officer or employee to have access to, and copy and verify any records or reports made by the investigator…”
Typical Questions in an Interview

- Delegation of authority: Who, when, where:
  - Screening of subjects
  - Interpreting screening results/admitting to the study
  - Informed consent of subjects
  - Receipt of test article; handling; administration; return
  - Reporting (including safety reporting) /transcribing data
  - Clinical laboratory
  - Training
  - Archiving study data
Clinical Investigator Inspections*
(All Centers, FY 2013)

CDER 361
CBER 91
CDRH 193
Total 645

*CDER numbers based on inspection start date – [OSI database as of January 31, 2014]
• CDRH numbers based on inspection end date, CBER numbers based on end date of classified inspections
• CDER: Center for Drug Evaluation and Research. CBER: Center for Biologics Evaluation and Research. CDRH: Center for Devices and Radiological Health.
Bioresearch Monitoring Program Inspections*
(CDER, FY 2013)

Clinical Investigator: 48%
Bioequivalence: 27%
Sponsor (GCP): 9%
Institutional Review Board/Radioactive Drug Research Committee: 12%
Good Laboratory Practice: 4%

754 BIMO Inspections

*Based on inspection start date – [OSI database as of January 31, 2014]
- IRB includes only CDER numbers – previously reported metrics may have combined data across CDER, CBER and CDRH
Clinical Investigator Inspections by Location*

(CDER, FY 2013)

- United States: 70%
- Western Europe: 11%
- Africa: 2%
- Asia/Pacific: 4%
- Eastern Europe: 9%
- Latin America: 3%

361 CI Inspections

*Based on inspection start date – [OSI database as of January 31, 2014]
International Clinical Investigator Inspections by Location* (CDER, FY 2013)

- Western Europe: 37%
- Africa: 7%
- Asia/Pacific: 14%
- Canada: 3%
- Eastern Europe: 30%
- Latin America: 9%

105 Inspections

*Based on inspection start date – [OSI database as of January 31, 2014]
Frequency of Clinical Investigator-Related Deficiencies Based on Post-Inspection Correspondence Issued*  
(CDER, FY 2013)

**Domestic CI Deficiencies**
- Protocol: 34%
- Records: 21%
- Consent: 9%
- Drug Accountability: 5%
- Adverse Events: 5%
- IRB Communication: 3%
- Total Domestic Inspections: 240

**Foreign CI Deficiencies**
- Protocol: 33%
- Records: 25%
- Consent: 8%
- Drug Accountability: 4%
- Other: 2%
- Adverse Events: 2%
- Total Foreign Inspections: 112

*Based on letter issue date; Inspections may have multiple deficiencies, [OSI database as of January 31, 2014]  
Note: this does not denote number of inspections completed, but rather number of inspection reports evaluated and closed in FY2013.
Compliance Classifications

**NAI** - No Action Indicated
 Inspected Entity is in compliance

**VAI** - Voluntary Action Indicated
 Minor deviation(s) from the regulations
 Voluntary correction is requested

**OAI** - Official Action Indicated
 Serious non-compliance requiring regulatory or administrative action by FDA
Inspectional Outcomes

- No Action Indicated
- Form FDA 483

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**
**FOOD AND DRUG ADMINISTRATION**

<table>
<thead>
<tr>
<th>DISTRICT OFFICE ADDRESS AND PHONE NUMBER</th>
<th>DATE(S) OF INSPECTION</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FEI NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT IS ISSUED</th>
</tr>
</thead>
<tbody>
<tr>
<td>TO:</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FIRM NAME</th>
<th>STREET ADDRESS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CITY, STATE AND ZIP CODE</th>
<th>TYPE OF ESTABLISHMENT INSpected</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

THIS DOCUMENT LISTS OBSERVATIONS MADE BY THE FDA REPRESENTATIVE(S) DURING THE INSPECTION OF YOUR FACILITY. THEY ARE INSPCTIONAL OBSERVATIONS, AND DO NOT REPRESENT A FINAL AGENCY DETERMINATION REGARDING YOUR COMPLIANCE. IF YOU HAVE AN OBJECTION REGARDING AN OBSERVATION, OR HAVE IMPLEMENTED, OR PLAN TO IMPLEMENT, CORRECTIVE ACTION IN RESPONSE TO AN OBSERVATION, YOU MAY DISCUS THE OBJECTION OR ACTION WITH THE FDA REPRESENTATIVE(S) DURING THE INSPECTION OR SUBMIT THIS INFORMATION TO FDA AT THE ADDRESS ABOVE. IF YOU HAVE ANY QUESTIONS, PLEASE CONTACT FDA AT THE PHONE NUMBER AND ADDRESS ABOVE.

DURING AN INSPECTION OF YOUR FIRM WE OBSERVED:

**Regarding your conduct of protocol**

OBSERVATION 1
Clinical Investigator Inspections Final Classification*
(FY 2013)

- No Action Indicated: 54%
- Voluntary Action Indicated: 43%
- Official Action Indicated: 3%

349 CI Inspections

*Based on Letter Issue date; Includes OAI Untitled Letters, [OSI database as of January 31, 2014]
Reference

Inspection Observations

Spreadsheets summarizing the areas of regulation cited on FDA's system-generated 483s by fiscal year

http://www.fda.gov/ICECI/EnforcementActions/ucm250720.htm
Reference

Inspections Classification Database and Search (Oct. 2008–March 2014)

Final inspection classification for inspections related to currently marketed FDA-regulated products. (Some information may be withheld from posting as to not interfere with enforcement action).

http://www.fda.gov/ICECI/Inspections/ucm222557.htm
Common mistakes – Risk factors for non-compliance

- Poor supervision and training of study staff
- Insufficient investigator involvement in study conduct
- Inappropriate delegation of study tasks to unqualified persons
- Failure to adequate protect study subjects
- Overworked investigator and study staff (e.g., too many subjects, complex study with large data collection, too many concurrent studies)
Regulatory Actions

- Warning Letter
- Notice of Initiation of Disqualification Proceedings and Opportunity to Explain (NIDPOE)
- Disqualification of clinical investigator
- Criminal Investigation by Office of Criminal Investigations (OCI)
  - Debarment
Form FDA 483 Response

- Engage in verbal discussion at close-out
- Send written response within 15 business days
- What not to say:
  - “The study monitor failed to inform the staff of IRB approval of a new version of Protocol XX”. *It is your responsibility as the investigator (not the monitor’s responsibility) to ensure that the IRB has approved any changes in the research prior to implementing those changes.*
  - The study coordinator miscalculated the WOMAC pain subscale. *Your response is inadequate because…you have submitted no documentation of the retraining.*
Screening ferritin value of 881.4 ng/ml was significantly higher than the protocol-allowed maximum value of 100 ng/ml.

- “No deviation occurred with reference to randomizing this subject because the subject was randomized per protocol prior to receiving central lab results; when I received the central lab results, I felt that the subject was stable enough to continue with the study. I monitored the subject closely and felt my clinical judgment was correct”. Protocol XX does not allow enrollment of subjects based solely on the clinical investigator’s judgment when the subject does not meet required inclusion criteria.
Reference

- List of Warning Letters
  
  http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/default.htm

- Regulatory Procedures Manual Section on Warning Letters
  
Investigator Disqualification

21 CFR 312.70

- Repeated and deliberate failure to comply with the requirements
- FDA provides notice of matter to investigator and provides opportunity to explain (informal hearing)
- Opportunity for formal hearing
- May result in ineligibility to receive investigational drugs
Reference

- Clinical Investigators- Disqualification Proceedings
  Provides a list of clinical investigators who are or have been subject to an administrative clinical investigator disqualification action and indicates the current status of that action
  - A Notice of Initiation of Disqualification Proceedings and Opportunity to Explain (NIDPOE)
  - The Notice of Opportunity for Hearing (NOOH)
  - Totally Restricted
  - Restricted

http://www.fda.gov/ICECI/EnforcementActions/ucm321308.htm
NOTICE OF INITIATION OF DISQUALIFICATION PROCEEDINGS AND OPPORTUNITY TO EXPLAIN (NIDPOE)

CERTIFIED MAIL
RETURN RECEIPT REQUESTED

Bertrand Agus, M.D.
251 East 33rd Street, 4th Floor
New York, NY 10016

Dear Dr. Agus:

Between October 25, 2006 and February 7, 2007, Andrew Paglia, D.P.M., representing the Food and Drug Administration (FDA), conducted an investigation and met with you to review your conduct of the following clinical study:

Protocol[ ] entitled “A Multicenter, Standard of Care-Controlled Study to Evaluate the Long-Term Safety of[ ] for the Treatment of Chronic Low Back Pain.”

This study of the investigational drug[ ] was performed for[ ]

This inspection is a part of the FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to ensure that the rights, safety, and welfare of the human subjects of the study have been protected.

Based on our evaluation of information obtained by the Agency, we believe that you have submitted false information to the sponsor and repeatedly or deliberately violated regulations governing the proper conduct of clinical studies involving investigational products as published under Title 21, Code of Federal Regulations (CFR), Part 312 (copy enclosed).
informed about their obligations. While you may delegate certain study tasks to individuals qualified to perform them, as clinical investigator, you must adequately supervise those to whom you delegate authority. Our inspection indicates that you failed to personally conduct or supervise the clinical investigation. Our inspection revealed that you had little personal involvement in the conduct of the study beyond conducting a limited number of physical examinations, reviewing a limited number of electrocardiograms (ECGs), and treating study related emergencies, and that your supervision of personnel to whom you delegated study tasks was not adequate to ensure that clinical trials were conducted according to the signed investigator statement, the investigational plan, and applicable regulations, in a manner that protected the rights, safety, and welfare of human subjects.
And more...

- Submission of false information [21 CFR 312.70].

The inspection report indicates that the FDA investigator conducted a phone interview with a subject on 11/14/2006 and the subject stated that he was only at the site for two visits. Review of the CRFs revealed that there were entries for a total of six visits for this subject. The CRFs document a screening visit on 1/19/06 and a baseline visit conducted on 2/9/06. Additional entries were made in the electronic CRFs for the week one, week two, month one and month 2, none of which were attended by the subject.
Reference

- FDA Debarment List (Drug Product Applications)
  Firms or individuals convicted of a felony under Federal law for conduct (by a firm) relating to the development or approval of any drug product or abbreviated drug application

http://www.fda.gov/ICECI/EnforcementActions/FDADebarmentList/default.htm
Dated: November 9, 2009.

Brenda Holman,
Acting Director, Office of Enforcement, Office of Regulatory Affairs.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2009–N–0288]

Anthony W. Albanese: Debarment Order

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) (the agency) is issuing an order under the Federal Food, Drug, and Cosmetic Act (the act) permanently debarring Anthony W. Albanese from providing services in any capacity to a person that has an approved or pending drug product application. We base this order on a finding that Mr. Albanese was convicted of a felony under Federal law for conduct relating to the regulation of a drug product under the act. Mr. Albanese was given notice of the proposed permanent debarment and an opportunity to request a hearing within the time frame prescribed by regulation. As of October 30, 2009, Mr. Albanese has failed to respond. Mr. Albanese’s failure to respond constitutes a waiver of his right to a hearing concerning this action.

DATES: This order is effective November 23, 2009.

ADDRESSES: Submit applications for Island entered judgment against Mr. Albanese for one count of conspiracy to sell drug samples in violation of 18 U.S.C. 371; one count of unlawful sale of drug samples in violation of 21 U.S.C. 331(a), 333(b)(4), and 555(c)(1); one count of health care fraud in violation of 18 U.S.C. 1347(a) and 2; and one count of money laundering in violation of 18 U.S.C. 1956(a)(1)(A)(i) and 2.

FDA’s finding that debarment is appropriate is based on the felony conviction related to the sale of drug samples. The factual basis for this conviction is as follows: From July 3, 2000, and continuing until on or about August 16, 2002, Mr. Albanese knowingly sold and offered to sell prescription drug samples that had been provided by pharmaceutical companies to Dr. Wallace E. Consalves, Jr. Mr. Albanese paid cash and goods in kind to Dr. Consalves for drug samples, removed the sample drugs from their packaging, and placed them for sale at his pharmacy as prescription drugs.

As a result of his conviction, FDA sent Mr. Albanese by certified mail on September 1, 2009, a notice proposing to permanently debar him from providing services in any capacity to a person that has an approved or pending drug product application. The proposal was based on a finding, under section 306(a)(2)(B) of the act that Mr. Albanese was convicted of a felony under Federal law for conduct relating to the regulation of a drug product under the act. The proposal also offered Mr. Albanese an opportunity to request a hearing, providing him 30 days from the date of receipt of the letter in which to file the request, and advised him that failure to request a hearing constituted a waiver of the opportunity for a hearing and of any contentions concerning this action. Mr. Albanese failed to respond.

Brenda Holman,
Acting Director, Office of Enforcement, Office of Regulatory Affairs.

[FR Doc. E9–28083 Filed 11–20–09; 8:45 am]
Abuses Endangered Veterans In Cancer Drug Experiments

By DEBORAH SONTAG

ALBANY — Carl M. Steubing, a decorated Battle of the Bulge veteran whose experience of war made him a pacifist but also instilled in him a zest for living life at full tilt, took his diagnosis of gastroesophageal cancer in 2001 as a challenge.

With a twinge of white hair and a rich baritone voice, Mr. Steubing, at 76, was not ready to succumb to illness. A retired music educator and wedding photographer, he remained active as a church choir director, expert cook, painter, golfer and fisherman. He was married to a woman 24 years his junior, and they had seven children and three grandchildren between them.

Mr. Steubing jumped at the chance to participate in an experimental drug study at the Stratton Veterans Affairs Medical Center in Albany, believing it offered him the hope of surviving longer. The research coordinator, Paul H. Kornak, told Mr. Steubing that he was “just a perfect specimen,” with the body of a man half his age, according to Jayne Steubing, Mr. Steubing’s widow.

He was not, though. Because of a previous cancer and poor kidney function, Mr. Steubing was not even eligible to participate in the experiment, according to government documents. Mr. Kornak, however, brushed that obstacle aside. He altered Mr. Steubing’s medical records, according to the V.A.

In 2001, Mr. Steubing endured about six periodic treatments with an aggressive three-drug chemotherapy combination. Each infusion made him violently ill and forced his hospitalization. He died in March 2002.

Last month, at the federal courthouse in Albany, Mrs. Steubing glared at Mr. Kornak, 53, as he pleaded guilty to fraud, making false statements and criminally negligent homicide in the death of an Air Force veteran, James DiGuglielmo. When Mr. Kornak admitted to falsifying the medical data of “subject initials CMS” — Carl M. Steubing — Mrs. Steubing’s face crumpled.

Mr. Kornak, who is scheduled to be sentenced in May, also agreed to cooperate in a widening investigation of the hospital’s cancer research program. From 1999 to 2003, when he worked there, scores of veterans were, at the least, put at risk. But allegations of carelessness, fraud and patient abuse in the hospital’s cancer research program predated Mr. Kornak, and employees say that administrators not only dismissed their concerns, but harassed them for standing up for the veterans.

“Research violations were a way of life at Stratton for 10 years,” said Jeffrey Pudin, a pharmacist at the hospital. “Stratton officials turned a blind eye to unethical cancer research practices and punished those who spoke out against them. The whole Kornak episode could have been prevented.”

According to Mr. Kornak’s lawyer, E. Stewart Jones, there was a “clear systems failure,” permitting a research culture where “rules weren’t followed, protocols weren’t applied and supervision was nonexistent.” It was also a culture whose de-

Routine Visit Leads to an Inquiry

In December 2001, a clinical research associate for Ilex Oncology made a routine visit to the Albany veterans’ hospital, where Ilex was sponsoring a bladder cancer study.

Ilex, a cancer drug company, was offering the Albany research program $2,500 for each study subject. Such payments are a standard practice, and many researchers say that they barely cover the cost of conducting the studies. Critics of drug-testing practices, however, consider the payments a threat to scientific integrity.

Ilex’s research associate discovered some paperwork that raised suspicions, according to Karen Arnstein, a spokeswoman for the Genzyme Corporation, which bought Ilex at the end of last year.

“Things about the dates didn’t look right,” Ms. Arnstein said. “If the results of a pathology report for a biopsy are dated prior to the biopsy being taken — something seemed off.”

The discrepancies led to an audit by Ilex. In the spring of 2002, the Albany hospital began an internal review of the cancer research program, eventually referring the matter to the inspector general, according to The Times Union.

Ilex shut down the Albany study and alerted the F.D.A. The agency had also received another complaint, an F.D.A. official said.

In September, however, the Food and Drug Administration started proceedings to disqualify Dr. Holland from conducting further clinical research because he had “failed to protect” subjects under his care in Albany.

According to the F.D.A., patients’ medical records were altered in at least five experimental drug studies, enabling veterans like Mr. Steubing to be enrolled in studies for which they were either too sick or too healthy to qualify. A patient with coronary disease, for instance, was enrolled in a study that excluded heart patients because of a risk of hemorrhages. A patient with impaired renal function was administered a drug toxic to kidneys that probably contributed to his death, the agency said.

Continued on Page 18

Paul H. Kornak, who posed as a doctor for veterans, in 1999.
Case Study: Lax Supervision

- Study coordinator enrolled ineligible subjects in oncology trials
- Coordinator altered source records and created fraudulent CRFs to make subjects appear eligible
- Data manipulations should have been apparent to attentive clinician
- Subject who was ineligible due to poor renal and liver function was enrolled, dosed, and died as a result
- Study coordinator sentenced to 71 months in prison and debarred from any future involvement in FDA regulated research
- Dr. Holland – 5 years probation, $500,000 restitution to defrauded drug companies, disqualified
How can clinical investigators ensure high quality data and subject safety?

- Select qualified staff and ensure adequate training and supervision
  - Ensure staff are not performing tasks they are not qualified to do (e.g. assessing eligibility, performing physical exams, assessing adverse events)
  - Ensure oversight of sub-investigators and study staff
Question?

Do you need a delegation log?

**ANSWER: NO.** Such a log is not an FDA requirement and is not listed in the list of essential documents in ICH E6 (although signature sheets are included).
Improve Process — Be Proactive

- Address human factors in systems
  - Hire experienced, qualified staff
  - Avoid conflicts of interest/financial incentives
  - Decrease number of times data are handled
  - Assess ability to comply with protocol visits; laboratory testing; electronic systems for data capture, archiving and transmission to sponsor; maintaining records, drug accountability, inspections by FDA
Improve Process — Be Proactive

Create systems that limit opportunity for errors
- Simplify protocol and outcomes assessed
- Be realistic about the amount of data to be collected
- Standardize systems and formats where possible
- Use validated instruments/definitions
- Write down all procedures (SOPs). Use checklists.
- Don’t re-invent the wheel
- Keep amendments to a minimum and check the CRFs and consent form against each change
Improve Process

- Develop an integrated framework
  - Data and Safety Monitoring Plan, Data Management Plan, Quality Assurance Plan, Data Analysis Plan
  - Insist on training and then test it
  - Think very carefully about unblinding procedures *Many examples of errors!*
  - Have a disaster plan (for staff turnover, floods, etc.)
  - Do beta-testing/dry-runs
  - Have weekly team meetings/calls
  - Audit yourself — be open and honest
Implement System to Detect and Correct Errors in Real Time

- Do real-time cleaning of the data
- Pay attention to monitoring queries and respond promptly *Close loops*
- Audit trail of changes should make clear what was changed, who changed it, and why it was changed
- Evaluate need for system-wide corrections and training
Key Messages

- Clinical investigators play a critical role in ensuring high quality studies.
- Good care of patients is not the same as Good Clinical Practices (GCP) in research.
  - Ensure that all staff have a clear understanding of responsibilities under FDA regulations.
- At stake is public confidence and participation in the clinical trials and ultimately the availability of safe and effective products.
The "cost of quality" isn't the price of creating a quality product or service. It's the cost of NOT creating a quality product or service.

FDA Sites of Interest

• Running Clinical Trials
  http://www.fda.gov/ScienceResearch/SpecialTopics/RunningClinicalTrials/default.htm

• FDA Basics for Industry
  http://www.fda.gov/ForIndustry/FDABasicsforIndustry/default.htm

• Sign up for Updates
  http://www.fda.gov/ForIndustry/FDABasicsforIndustry/ucm234630.htm
• Replies to Inquiries to FDA on Good Clinical Practice
  – Designed to simplify the search for copies of e-mail messages (including the original inquiry and associated reply(ies)) that have been submitted by the public to the Good Clinical Practice Program's gcp.questions@fda.hhs.gov e-mail account.

http://www.fda.gov/ScienceResearch/SpecialTopics/RunningClinicalTrials/RepliestoInquiriestoFDAonGoodClinicalPractice/default.htm
Guidances of Interest

• FDA Inspections of Clinical Investigators-Information sheet

• Guidance for Industry-Investigator Responsibilities
Webpage for Sponsor-Investigators!

Investigator-Initiated Investigational New Drug (IND) Applications webpage

- Brief explanations about various aspects of IND application submissions and procedures with links to guidances, references, and forms.

Thank you for your attention